Insider Selling: Natera Inc (NASDAQ:NTRA) CTO Sells 1,033 Shares of Stock
Natera Inc (NASDAQ:NTRA) CTO Jonathan Sheena sold 1,033 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $29.50, for a total value of $30,473.50. Following the completion of the transaction, the chief technology officer now owns 241,937 shares in the company, valued at $7,137,141.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Jonathan Sheena also recently made the following trade(s):
- On Friday, August 9th, Jonathan Sheena sold 250,000 shares of Natera stock. The stock was sold at an average price of $31.37, for a total value of $7,842,500.00.
- On Monday, June 24th, Jonathan Sheena sold 500 shares of Natera stock. The shares were sold at an average price of $25.19, for a total value of $12,595.00.
Natera stock traded up $0.55 during mid-day trading on Wednesday, hitting $30.55. The stock had a trading volume of 529,134 shares, compared to its average volume of 680,728. Natera Inc has a one year low of $11.08 and a one year high of $33.55. The company has a current ratio of 2.54, a quick ratio of 2.42 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $2.08 billion, a P/E ratio of -14.21 and a beta of 1.43. The firm’s 50 day moving average is $29.82 and its 200 day moving average is $23.68.
A number of research analysts have weighed in on the company. Craig Hallum increased their target price on Natera from $29.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 8th. BidaskClub upgraded Natera from a “hold” rating to a “buy” rating in a research note on Friday, August 9th. Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Friday, August 9th. Canaccord Genuity increased their price objective on shares of Natera from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Natera in a report on Thursday, August 22nd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Natera presently has a consensus rating of “Buy” and a consensus target price of $32.57.
Institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE grew its position in Natera by 575.2% in the second quarter. US Bancorp DE now owns 3,099 shares of the medical research company’s stock worth $86,000 after acquiring an additional 2,640 shares in the last quarter. Focused Wealth Management Inc purchased a new stake in Natera during the second quarter valued at approximately $83,000. State Board of Administration of Florida Retirement System lifted its stake in shares of Natera by 37.2% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,755 shares of the medical research company’s stock valued at $435,000 after purchasing an additional 4,270 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Natera in the 2nd quarter valued at approximately $129,000. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Natera by 134.3% in the 2nd quarter. Meeder Asset Management Inc. now owns 8,958 shares of the medical research company’s stock worth $248,000 after purchasing an additional 5,135 shares during the period. 94.95% of the stock is currently owned by institutional investors.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: CD Ladder
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.